The series of T&S deals. And I think one thing that you’ll see from us, Charles is, an announcement like today with a number of partnerships is an important piece of the path to $300 million, right? Because while these partnerships are strong margin partnerships, we can add a lot of value to the clients and they can enhance our EBITDA. They don’t have a lot of top line. They tend to be pretty small given the PMPMs. So that’s how I would think about it in terms of where are we starting pro forma today of about $190 million, how are we adding from there based on the current Performance Suite book, and then adding on top of that to the $300 million. And the last thing just to be [indiscernible] is the rollout of the NIA synergies that we talked about at the time of that deal which is $35 million in total.
Charles Rhyee: Okay. And then I guess, to follow-up on the question about redeterminations, I think in particular, Illinois is a big one, and that started July 1st. Any kind of sense that you’ve gotten there on the progress or lack of progress perhaps. Are they one of the states that are taking into consideration sort of the procedural issues?
John Johnson: They certainly seem to be, yes. I think if you read some of the notes that have come out of the state government and health agencies it seems to us that they’re taking a very deliberate approach there to support their citizens. It’s also too early to see in the numbers.
Charles Rhyee: Okay. Fair enough. I’m sorry, just one follow-up on another question. I think Sean asked about sort of the acuity in how you would see it. You talked about leading indicators. How early would those – in those leading indicators, would you be able to notice something changing? I know you talked about seeing the pre-ops, but maybe any other factors that would give you some lead time in seeing changes? Thanks.
John Johnson: That’s going to be the big one, Charles, because that contains a lot of information, right? It’s not just the information around the requested treatments, but it’s also what’s the diagnosis, what’s the history of disease and all of those different factors. So that’s an inclusive set of information.
Charles Rhyee: Okay. Great. Thanks a lot.
Operator: The next question comes from David Larsen with BTIG. Please go ahead.
David Larsen: Hi. Can you talk a little bit about Bright Health? Like how much revenue is coming from that in 2023? And then I think Molina is buying a significant portion of them. Are you going to recapture that revenue through Molina in 2024? Any color there would be very helpful. Thank you.
John Johnson: Yes. So on Bright, we’ve indicated an expectation for total revenue this year between $30 million and $40 million that is related to the wind down of their IFP lives and not related to any of their Medicare Advantage lives, which is a plan that Molina is purchasing. It said that is a plan that we had not done any work with.
David Larsen: Okay. That’s great. Thanks. And then can you maybe talk a little bit more about the expansion with Molina in Florida and that Medicaid book and that process, just any more color there? And then are other states looking at that, and I mean, does that increase your odds of winning business in like, Texas, for example Medicaid?
Seth Blackley: Yes, David, it’s Seth. I can take that one. It’s a lot like the other six states that came before Florida, and it’s really a process of working with the local leadership to build confidence around our ability to drive savings and the internal reference ability within the other states in the markets, which we got to continue to perform. And I think each time we add a state, it’s good evidence that we’re delivering on our commitments. And I think it will be the same for states eight, nine and beyond. And look, we’re pretty heads down focused on execution. We feel like we do a good job for our clients. This is what comes out of the back of it, and we feel really good about that partnership and continuing to deliver a lot of value, David, on it.
